⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910625 | 0.85 | — | — | |
| SCHEMBL4720982 | 0.83 | NOS2 (0.52) | — | |
| SCHEMBL890174 | 0.79 | — | — | |
| SCHEMBL12060991 | 0.79 | — | — | |
| SCHEMBL22332736 | 0.79 | — | — | |
| SCHEMBL5771317 | 0.79 | — | — | |
| SCHEMBL2321562 | 0.79 | — | — | |
| SCHEMBL13064286 | 0.79 | — | — | |
| Bromide SCHEMBL6143076 | 0.77 | — | — | |
| SCHEMBL5574453 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204407-B1 | PROCESS | GIVAUDAN SA (CH) | 2024-06-19 | — | — | EP | claimed |
| US-20230312506-A1 | PROCESS | GIVAUDAN SA (CH) | 2023-10-05 | — | — | US | claimed |
| EP-4204407-A1 | PROCESS | Givaudan SA (CH) | 2023-07-05 | — | — | EP | claimed |
| CN-116209659-A | Method | 奇华顿股份有限公司 | 2023-06-02 | — | — | CN | claimed |
| EP-2202577-B1 | Chemically amplified positive resist composition and resist patterning process | SHINETSU CHEMICAL CO (JP) | 2014-08-27 | — | — | EP | claimed |
| US-6017889-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-01-25 | — | — | US | claimed |
| EP-0740655-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-10-20 | — | — | EP | claimed |
| US-5902791-A | TREATING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, GINGIVITIS, CORNEAL ULCERATION OR TUMOR METASTASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-05-11 | — | — | US | claimed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
| EP-4204407-B1 | PROCESS | GIVAUDAN SA (CH) | 2024-06-19 | — | — | EP | disclosed |
| US-20240139087-A1 | ORGANIC COMPOUNDS AS TRPM8 ACTIVATORS | GIVAUDAN SA (CH) | 2024-05-02 | — | — | US | disclosed |
| US-20240134280-A1 | Polymer, Chemically Amplified Positive Resist Composition, Resist Patterning Process, And Mask Blank | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | GIVAUDAN SA (CH) | 2024-04-25 | — | — | US | disclosed |
| US-20240118613-A1 | CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION AND RESIST PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-04-11 | — | — | US | disclosed |
| US-5902791-A | TREATING RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, GINGIVITIS, CORNEAL ULCERATION OR TUMOR METASTASES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-05-11 | — | — | US | disclosed |
| EP-0861226-A1 | SYNTHESIS OF CARBOXYLIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997019050-A1 | SYNTHESIS OF CARBOXYLIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |